Brief Report

Excessive dopamine neuron loss in progressive supranuclear palsy

  1. Karen E. Murphy BSc(Hons)1,
  2. Tanya Karaconji BSc(Hons)2,
  3. Craig D. Hardman PhD2,
  4. Glenda M. Halliday PhD1,*

Article first published online: 28 DEC 2007

DOI: 10.1002/mds.21907

Issue

Movement Disorders

Movement Disorders

Volume 23, Issue 4, pages 607–610, 15 March 2008

Additional Information

How to Cite

Murphy, K. E., Karaconji, T., Hardman, C. D. and Halliday, G. M. (2008), Excessive dopamine neuron loss in progressive supranuclear palsy. Mov. Disord., 23: 607–610. doi: 10.1002/mds.21907

Author Information

  1. 1

    Prince of Wales Medical Research Institute, Randwick, Australia

  2. 2

    Department of Anatomy, School of Medical Sciences, University of New South Wales, Sydney, Australia

*Prince of Wales Medical Research Institute, Barker Street, Randwick, NSW 2031, Australia

Publication History

  1. Issue published online: 26 MAR 2008
  2. Article first published online: 28 DEC 2007
  3. Manuscript Accepted: 20 NOV 2007
  4. Manuscript Received: 20 SEP 2007

Funded by

  • National Health and Medical Research Council of Australia. Grant Number: 222727

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (97K)

Keywords:

  • midbrain;
  • dopamine neurons;
  • progressive supranuclear palsy;
  • Parkinson's disease;
  • neurodegeneration

Abstract

Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy. © 2007 Movement Disorder Society

View Full Article (HTML) Get PDF (97K)